zervimesine
CT1812 Small Molecule Target: σ-2 receptor, S2R complex
Cognition Therapeutics
Most recent annual filing: 2026-01-15
- Capital raise / ATM filing2H 2026Capital raise / ATM filing, 2H 2026, notable
- CGTX corporate OpEx financing3Q 2026CGTX corporate OpEx financing, 3Q 2026, routine
- START Phase 2 MCI Ph22027START Phase 2 MCI Ph2, 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (2 active programs)
Discontinued (1)
- zervimesine — Geographic Atrophy · voluntarily discontinued to focus resources on dementia programs in AD and DLB; not related to safety concerns
Biotech Distilled coverage (11)
- 2026-08-07 UPDATE: Cognition Therapeutics (CGTX) — The Dilution Gap Keeps Shrinking, and the Patent Clock Just Moved Ten Years 🔒 Paid
- 2026-06-24 UPDATE: Cognition Therapeutics (CGTX) — The Minutes Landed. The Stock Didn’t Get the Memo. 🔒 Paid
- 2026-05-21 UPDATE: Cognition Therapeutics (CGTX) - The May 20 Meeting Cleared, Now We Wait for the Minutes 🔒 Paid
- 2026-05-08 UPDATE: Cognition Therapeutics (CGTX) - The Psychosis Catalyst Has a Date 🔒 Paid
- 2026-03-29 UPDATE: Cognition Therapeutics (CGTX) - The Reality Check and a 30% Haircut 🔒 Paid
- 2026-03-22 UPDATE: Cognition Therapeutics (CGTX) – Showing the Math at AD/PD 🔒 Paid
- 2026-03-07 UPDATE: Cognition Therapeutics (CGTX) – The Psychosis Pivot is a Regulatory Masterstroke 🔒 Paid
- 2026-02-07 UPDATE: Cognition Therapeutics (CGTX) – Patients Vote Yes (But the Market Still Seems to Be Waiting) 🔒 Paid
- 2026-01-30 UPDATE: Cognition Therapeutics (CGTX) - The Phase 3 Dream Just Became a Phase 2b Reality Check 🔒 Paid
- 2026-01-07 UPDATE: Cognition Therapeutics (CGTX) Prints Some Receipts for DLB 🔒 Paid
- 2026-01-01 Cognition Therapeutics (CGTX): Scientific Due Diligence for Zervimesine 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.